AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04507529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-mentoring
Description: Patients (mentees) are matched with a peer-mentor. Throughout the intervention period (24 weeks), the mentee and the mentor will have informal telephone contact and meet face-to face approximately 8 times during the intervention period.
Study NCT04093167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Per current Product Monograph/U.S. Drug Label and/or local guidelines.
Study NCT04093167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Per current Product Monograph/U.S. Drug Label and/or local guidelines.
Study NCT01317420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Intravenous infusion once every three weeks
Study NCT01111630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recomon (Epoetin Beta)
Description: administer once weekly
Study NCT01111630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recomon (Epoetin Beta)
Description: administer three times weekly
Study NCT03329586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity training
Description: 6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
Study NCT01465893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: vitamin D ,50000 unit /week
Study NCT01465893 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vitamin D withheld
Description: do not receive anything
Study NCT03748498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
Study NCT03748498 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laser
Description: Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
Study NCT01283269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support System
Description: Training in use of a memory notebook system
Study NCT01283269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Training
Description: Computer brain fitness training
Study NCT03958903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amygdala recording and stimulation using Neuropace RNS
Description: Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
Study NCT03958903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral tasks
Description: Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
Study NCT00283504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANTI-IGE THERAPY (XOLAIR)
Description: Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
Study NCT02328326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-IMPACT
Description: Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
Study NCT02328326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PACT
Description: participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
Study NCT02958436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Study NCT02958436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02556021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg
Description: CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
Study NCT02556021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg
Description: CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
Study NCT02556021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablet, once daily, oral administration for up to 4 weeks
Study NCT00737841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve
Description: 1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
Study NCT00737841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
Study NCT03466580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Carer Support Needs Assessment Tool (CSNAT) intervention
Description: The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
Study NCT03727191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (education, guidelines, recommendations)
Description: Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
Study NCT03727191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group (education, guidelines, 2 pckts diet, recommendations)
Description: Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
Study NCT02352064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET (18-FDG)
Description: Every patient will have a PET
Study NCT00986999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
Study NCT01153646 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: pHIV7-shI-TAR-CCR5RZ treated CD4 cells
Description: Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
Study NCT03852953 — intervention group
Intervention type: OTHER
Intervention: Under- or overdiagnosed cancer
Description: Diagnosed with a cancer that was visible on prior mammograms
Study NCT04287374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component Well-being Intervention
Description: The intervention asks participants to complete exercises based on three different skills. These skills include cognitive restructuring, gratitude and behavioral activation. After completing the program, participants will pick their favorite exercise to complete on a weekly basis for homework. In order to increase compliance with the homework, participants will complete a short plan in which they will identify when, where and with who they will complete the homework. The whole intervention takes approximately 20-30 minutes to complete.
Study NCT04287374 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Study Skills
Description: Participants are taught three different study skills/strategies. They are asked to make a plan to continue using these strategies after completing the intervention. The whole intervention takes approximately 20-30 minutes to complete.
Study NCT03675386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional Group
Description: The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance \& Commitment Therapy (ACT) and e-mobile self-management tools.
Study NCT03675386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
Study NCT03741309 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Calcium sodium phosphosilicate
Description: Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
Study NCT03741309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dentrifice
Description: placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
Study NCT02542748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: norepinephrine injection
Study NCT02542748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ephedrine
Description: Ephedrine injection
Study NCT04367922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Emotion Skills Course
Description: The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
Study NCT02197754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet
Description: Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives.
Study NCT03365219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis O-Ring Wound Retractor
Description: A flexible self-retaining plastic Alexis retractor was used in place of standard surgical retractors.
Study NCT03365219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Surgical Retractors
Description: Routine hand-held metal retractors as needed by the surgical team
Study NCT01273922 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NDV-3 investigational vaccine
Description: Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
Study NCT01523522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myoblast injection
Description: Autologous myoblast injection in the anal sphincter
Study NCT01523522 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline solution injection
Description: saline solution injection in anal sphincter
Study NCT01077349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high volume hemofiltration
Description: (80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being \<35 ml/kg/h (or a maximum of 3500 ml/h).
Study NCT01077349 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: extra-renal replacement therapy (CVVHDF mode, total effluent \<35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~* Serum creatinine > 350 micromol/L or increase x3.0 from pre-operative value OR~* Diuresis \< 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~* Or serum urea > 36 mmol/l OR~* Or life threatening hyperkalemia
Study NCT03338049 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Veran System
Description: Electromagnetic navigation bronchoscopy and electromagnetic navigation transthoracic needle aspiration
Study NCT01493726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, Low dose
Description: IM injection, given monthly
Study NCT01493726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, Med dose
Description: IM injection, given monthly
Study NCT01493726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, High dose
Description: IM injection, given monthly
Study NCT01493726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed matched placebo IM injection, given monthly
Study NCT02966522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT02966522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01235858 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: wearing of sterile gowns
Description: Anesthesiologists wearing sterile gown for epidural insertion
Study NCT01235858 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No gown
Description: Anesthesiologists not wearing sterile gown for epidural insertion
Study NCT05332080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation via application on cell phone
Description: Realization of rehabilitation through content in an app they received advice on self-care and the type of exercises to do. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned goals.
Study NCT04496778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy ( laser acupuncture combined with nasal laser irradiation)
Description: Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity
Study NCT02987413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal stem cells (MSCs)
Description: 2 intrathecal autologous MSCs infusions (1x10\^8 cells) will be performed, escalated from 30 days apart
Study NCT02268838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Study NCT04496778 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low level laser therapy ( laser acupuncture combined with nasal laser irradiation)
Description: Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity
Study NCT04496778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: 3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
Study NCT04496778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aerobic exercise
Description: 3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
Study NCT02222285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Food : Vayarin_005
Study NCT02268838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007 matching placebo
Study NCT03291444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cells
Description: After pretreatment, chimeric antigen receptor T cells will be transfused.
Study NCT02222285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03291444 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chimeric antigen receptor T cells
Description: After pretreatment, chimeric antigen receptor T cells will be transfused.
Study NCT03291444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptide specific dendritic cell
Description: After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TNF inhibitors
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF inhibitors
Study NCT00254722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow precursor cell harvest and transplant
Description: Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10\^6 mononuclear cells/kg body weight, administered within 36 hours of injury
Study NCT02222285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03852953 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Invited or attended BreastScreen Norway
Study NCT01974518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab and Cyclophosphamide IV
Study NCT03792841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acapatamab
Description: Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
Study NCT00808210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Intravenous repeating dose
Study NCT00808210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral or parenteral repeating dose
Study NCT00808210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose
Study NCT00808210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous repeating dose
Study NCT00808210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous repeating dose
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF inhibitors
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Synthetic DMARD(s)
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic DMARD(s)
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic DMARD(s)
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Co-medication: Synthetic DMARDs
Description: Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-medication: Synthetic DMARDs
Description: Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
Study NCT01881308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-medication: Synthetic DMARDs
Description: Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
Study NCT00748436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine dihydrochloride
Description: (24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
Study NCT00748436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine dihydrochloride
Description: (24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
Study NCT00748436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: (placebo tablet + placebo tablet) BID per os 12 weeks
Study NCT01318187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1 gr
Study NCT01318187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1 gr
Study NCT01318187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: 0.1mg/kg intravenous in 100 ml serum physiologic